Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxAlcohol Drinking Cut in Half with Diabetes Medication

Could semaglutide be a new ally in alcohol dependence treatment?


A potentially groundbreaking approach in the treatment of alcohol dependence is being examined through the repurposing of semaglutide, a drug currently employed in managing type 2 diabetes and obesity. Preliminary research suggests that this medication significantly reduces alcohol consumption and relapses in alcohol-dependent individuals.

Key Points:
  • Semaglutide, a drug used for type 2 diabetes and obesity, could be an effective treatment for alcohol dependence according to a study from the University of Gothenburg.
  • The drug was found to reduce alcohol relapse drinking and alcohol intake in rats by over half.
  • Semaglutide is the first GLP-1 receptor-acting medication available in tablet form.
  • The drug may be most beneficial for patients suffering from both overweight and alcohol dependence.
Additional Points:
  • Current treatments for alcohol dependence include a combination of psychosocial methods and medications, with efficacy varying due to the multifaceted nature of the disease.
  • The study also indicated that semaglutide’s effect on reducing alcohol consumption could be due to its impact on the brain’s reward system, specifically the nucleus accumbens area.
  • The treated rats, both male and female, cut their alcohol intake by half compared to untreated ones.
Conclusion:
  • Although the study shows promise, clinical studies on humans are needed to confirm the effectiveness of semaglutide in treating alcohol dependence. If validated, this discovery could offer a significant advancement in the medical treatment of alcohol dependence.

Endocrinology Latest Posts

“Alcohol activates the brain’s reward system, resulting in the release of dopamine, something that is seen in both humans and animals. This process is blocked by the medication in mice, and with our interpretation, this could cause a reduction in the alcohol-induced reward.”

Cajsa Aranäs, doctoral student at Sahlgrenska Academy at the University of Gothenburg
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form